Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Rabies Vaccine (Vero Cell) developed by Zhuoyi Biological is an inactivated, freeze-dried vaccine intended for human use to prevent rabies infection. Produced using Vero cell culture technology, the vaccine utilizes the CTN-1V fixed rabies virus strain, which is inactivated with beta-propiolactone and highly purified. It is indicated for both pre-exposure immunization in high-risk individuals and post-exposure prophylaxis following potential rabies virus exposure. The vaccine works by inducing the production of neutralizing antibodies against the rabies virus, providing active immunity. It is approved and marketed in China, contributing to the country's rabies control and prevention efforts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rabies vaccine (vero cell) (Zhuoyi Biological).